CD22-targeted immunotherapy for B-cell acute lymphoblastic leukemia progressing following CD19-targeted immunotherapy - PubMed
6 hours ago
- #B-cell acute lymphoblastic leukemia
- #relapse after CD19 therapy
- #CD22-targeted immunotherapy
- The study retrospectively analyzed 43 patients with relapsed/refractory B-ALL who progressed after CD19-targeted immunotherapy.
- After CD19-targeted therapy, 34.9% of patients had CD19-negative relapse, while others maintained CD19 expression; subsequent treatments included CD22 CAR-T cells (55.8%) and Inotuzumab Ozogamicin (44.2%).
- The overall complete response/complete response with incomplete hematologic recovery rate was 54%, with 35.1% achieving minimal residual disease negativity; among responders, 59.1% relapsed.
- Multivariate analysis showed similar remission rates and survival for CD22 CAR-T and Inotuzumab Ozogamicin therapies; extramedullary disease and prior resistance to CD19-targeted therapy were linked to worse outcomes.
- CD22-targeted therapies provide a potential option for patients progressing after CD19-targeted immunotherapy, but high relapse rates indicate a need for improved strategies for durable remission.